Quest Diagnostics Incorporated
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Quest Diagnostics Incorporated
Private Company Edition: ReCode’s series B venture capital round grew for a third time, now totaling $260m for precision genetic medicines. Also, DalCor closed an $80m series D, manufacturer Nephron amassed $350m, Hyku launched with a $56m seed financing and Magnet emerged with $50m.
Ampersand Biomedicines has emerged from stealth mode with a new CEO, and aims to shake up oncology and immunology with a new tissue-specific approach to targeting medicines.
Public Company Edition: Neumora grossed $250m and RayzeBio raised $311m in the first initial public offerings since early August. Also, ImmunityBio completes $470m in equity and debt financings, Bausch + Lomb sells $1.4bn worth of notes and Arbutus is among firms making cuts to conserve cash.
The two partners are committing $100m to a 10-program effort combining Pfizer’s R&D capabilities with technologies and modalities housed within Flagship Pioneering and its portfolio companies.
- Diagnostic Imaging Services
- Other Names / Subsidiaries
- ADI Holding Company
- Athena Diagnostics
- Blueprint Genetics
- Boyce and Bynum Pathology Laboratories
- California Laboratory Associates (CLA)
- Celera Group
- Cleveland HeartLab Inc.
- Hurley Medical Center
- Pathway Diagnostics
- Shiel Medical Laboratory
- Solstas Lab Partners
- Summit Health
- Superior Mobile Medics
- Mid America Clinical Laboratories (MACL)
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.